GERN Stock Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.31 |
52 Week High | US$3.74 |
52 Week Low | US$1.64 |
Beta | 0.55 |
1 Month Change | 59.90% |
3 Month Change | 53.95% |
1 Year Change | 48.43% |
3 Year Change | 109.49% |
5 Year Change | 89.14% |
Change since IPO | -57.29% |
Recent News & Updates
Recent updates
Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued
Dec 20Geron: A Major Catalyst For Shareholders Arrives In January - At Last
Sep 16Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?
Sep 14Geron rises on narrower-than-expected Q2 loss
Aug 12Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt
Aug 05Geron: Waiting For Godot
Jul 15Geron: TLR Is 10 Months Away
May 03Is Geron (NASDAQ:GERN) Using Too Much Debt?
Feb 25Geron: Just One More Year Of Patience, Then Decision Time
Feb 23With No Catalysts At ASH, Geron Corp. Remains In A Holding Pattern
Nov 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
Nov 04Geron: Still A Strong Buy After New Phase II Data And 20% Return
Oct 22Geron: Potential For Mind-Bending Returns With Current Pipeline
Aug 19Shareholder Returns
GERN | US Biotechs | US Market | |
---|---|---|---|
7D | -3.8% | 0.9% | 0.4% |
1Y | 48.4% | 10.3% | 28.8% |
Return vs Industry: GERN exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: GERN exceeded the US Market which returned 29.5% over the past year.
Price Volatility
GERN volatility | |
---|---|
GERN Average Weekly Movement | 28.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GERN's share price has been volatile over the past 3 months.
Volatility Over Time: GERN's weekly volatility has increased from 16% to 29% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 141 | Chip Scarlett | https://www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
GERN fundamental statistics | |
---|---|
Market cap | US$1.95b |
Earnings (TTM) | -US$184.13m |
Revenue (TTM) | US$237.00k |
8,213x
P/S Ratio-10.6x
P/E RatioIs GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GERN income statement (TTM) | |
---|---|
Revenue | US$237.00k |
Cost of Revenue | US$123.74m |
Gross Profit | -US$123.50m |
Other Expenses | US$60.62m |
Earnings | -US$184.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.31 |
Gross Margin | -52,110.97% |
Net Profit Margin | -77,690.72% |
Debt/Equity Ratio | 33.0% |
How did GERN perform over the long term?
See historical performance and comparison